Teclistamab‑talquetamab combo showed an 89% lower risk of disease progression or death in a phase 3 trial for relapsed or refractory multiple myeloma, according to topline data released this week.
Trial results and comparison with existing therapies
MonumenTAL‑6, a global three‑arm study (NCT06208150), evaluated two bispecific antibodies—teclistamab, which targets B‑cell maturation antigen, and talquetamab, which targets GPRC5D—against standard regimens of elotuzumab‑pomalidomide‑dexamethasone or pomalidomide‑bortezomib‑dexamethasone. Patients had previously received one to four lines of therapy, including an anti‑CD38 antibody and lenalidomide.
Both investigational arms met the primary endpoint of progression‑free survival. The teclistamab‑talquetamab duo cut the risk of progression or death by 89% (hazard ratio 0.11; 95 % CI 0.08‑0.16; p < 0.0001). A second arm pairing talquetamab with pomalidomide reduced that risk by 73% (HR 0.27; 95 % CI 0.20‑0.35). An independent data monitoring committee recommended unblinding after the first interim analysis because of the strength of the findings.
Earlier phase 3 data on teclistamab monotherapy (MajesTEC‑9) reported a 71% reduction in progression or death and a 40% overall survival benefit in a similar CD38‑exposed group. The new combination appears to outperform those figures, though cross‑trial comparisons are limited by differing patient mixes.
Unlike the MajesTEC‑3 trial, which mainly enrolled CD38‑naïve patients, MonumenTAL‑6 enrolled a heavily pre‑treated cohort, with roughly 80 % refractory to daratumumab. This distinction is important for payers, as a more resistant population may demand different reimbursement considerations.
Related: Internet users report widespread access blocks
Implications for treatment sequencing and access
Johnson & Johnson’s global oncology therapeutic area head, Yusri Elsayed, MD, PhD, indicated the doublet will likely be limited to a “very, very small percentage of patients,” perhaps those treated at large academic centers with high progression risk. He suggested most earlier‑line patients will continue to receive daratumumab‑teclistamab or CAR T‑cell products such as ciltacabtagene autoleucel.
Using two bispecific mechanisms early could reduce options later, since GPRC5D‑directed agents have shown activity after BCMA‑targeted therapy failures. This trade‑off mirrors broader discussions about preserving future lines of therapy while delivering strong upfront responses.
From a broader perspective, the data highlight how emerging immunotherapies are reshaping the myeloma treatment setting. As more bispecific antibodies and CAR T‑cell products become available, clinicians must balance immediate efficacy with long‑term treatment planning, especially given the infrastructure needed to manage cytokine release syndrome and neurologic toxicity.
Structural barriers—including the need for specialized infusion centers and disparities in geographic access—remain a challenge for both bispecifics and CAR T‑cell approaches. Health‑system planners will need to consider site‑of‑care capacity and cost implications, not just clinical outcomes, when deciding how broadly to adopt the teclistamab‑talquetamab regimen.
For managed‑care stakeholders, the trial shows that sequencing strategy, site‑of‑care capacity, and long‑term cost comparisons will likely drive adoption more than efficacy alone.
